A summary of a workshop at the U.S. Conference on AIDS titled "The Consensus: Communicating About HIV Treatment as Prevention (TasP)."
Three experts share their perspectives on treatment as prevention (TasP) at the U.S. Conference on AIDS.
What do on-demand PrEP advances seen in men mean for a developing a biomedical prevention agenda for women?
At this year's AIDS 2018 in Amsterdam, Fauci detailed the scientific research that lead us on the path to the discovery that undetectable equals untransmittable (U=U).
Results from the PARTNER2 study, presented by Alison Rodger at AIDS 2018, yielded an equivalent level of confidence for gay men as it had for heterosexual couples in the original PARTNER study several years ago.
Earlier this year, urology resident Philip Cheng, M.D., appeared on the front page of The New York Times explaining his situation. Now, in a podcast, he tells Paul Sax, M.D., more about himself and the events surrounding his decision to go public....
Leading researchers and clinicians who influence best practices for conversations about the direct and indirect impact of HIV infection and treatment agree that communications regarding transmission must shift.
Researchers examining issues facing post-exposure prophylaxis (PEP) users found that 74% of study participants had at least one psychosocial issue, including depression and/or problematic drug or alcohol use.
Broad PrEP Access in Australia Reduces HIV Infections Even With Reduced Condom Use by People Not on PrEP
A controversial new study is wrongly driving prejudice against PrEP, according to Simon Collins.
An experimental vaccine regimen based on the structure of a vulnerable site on HIV elicited antibodies in mice, guinea pigs and monkeys that neutralize dozens of HIV strains from around the world.